Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MIDAZOLAM IN 0 9 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MIDAZOLAM IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance, leading to neuronal hyperpolarization and central nervous system depression.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Initial: 0.5-2 mg IV over 2-3 min; titrate by 0.5-1 mg increments q2-3min as needed; usual total 2.5-5 mg. Continuous infusion: 0.02-0.1 mg/kg/hr IV (1-7 mg/hr). Intranasal: 0.2-0.3 mg/kg (max 15 mg).
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
2-6 hours (prolonged in elderly, obesity, hepatic impairment, or critical illness; up to 12 hours in ICU patients)
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: ~80% as metabolites (primarily 1-hydroxymidazolam glucuronide), <1% unchanged; biliary/fecal: ~2-10%
Category C
Category A/B
Electrolyte
Electrolyte